147 related articles for article (PubMed ID: 36882122)
101. Characterization of site-specific glycosylation of secreted proteins associated with multi-drug resistance of gastric cancer.
Wu J; Qin H; Li T; Cheng K; Dong J; Tian M; Chai N; Guo H; Li J; You X; Dong M; Ye M; Nie Y; Zou H; Fan D
Oncotarget; 2016 May; 7(18):25315-27. PubMed ID: 27015365
[TBL] [Abstract][Full Text] [Related]
102. Pan-cancer analysis of altered glycosyltransferases confers poor clinical outcomes.
Marimuthu S; Batra SK; Ponnusamy MP
Clin Transl Discov; 2022 Jun; 2(2):. PubMed ID: 35875597
[No Abstract] [Full Text] [Related]
103. Correction: Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential.
Zhu TY; Hong LL; Ling ZQ
Biomark Res; 2023 Jul; 11(1):72. PubMed ID: 37480096
[No Abstract] [Full Text] [Related]
104. Bavachin alleviates diabetic nephropathy in db/db mice by inhibition of oxidative stress and improvement of mitochondria function.
Park J; Seo E; Jun HS
Biomed Pharmacother; 2023 May; 161():114479. PubMed ID: 36921531
[TBL] [Abstract][Full Text] [Related]
105. Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib.
Eun JW; Yoon JH; Ahn HR; Kim S; Kim YB; Lim SB; Park W; Kang TW; Baek GO; Yoon MG; Son JA; Weon JH; Kim SS; Cho HJ; Cheong JY
Cancer Commun (Lond); 2023 Apr; 43(4):455-479. PubMed ID: 36919193
[TBL] [Abstract][Full Text] [Related]
106. Delivery of anti-microRNA-21 by lung-targeted liposomes for pulmonary fibrosis treatment.
Yan L; Su Y; Hsia I; Xu Y; Vincent-Chong VK; Mojica W; Seshadri M; Zhao R; Wu Y
Mol Ther Nucleic Acids; 2023 Jun; 32():36-47. PubMed ID: 36919116
[TBL] [Abstract][Full Text] [Related]
107. TMT quantitative proteomics and network pharmacology reveal the mechanism by which asiaticoside regulates the JAK2/STAT3 signaling pathway to inhibit peritoneal fibrosis.
Sun J; Tang L; Shan Y; Yu M; Sheng L; Huang L; Cao H; Dai H; Wang F; Zhao J; Sheng M
J Ethnopharmacol; 2023 Jun; 309():116343. PubMed ID: 36906159
[TBL] [Abstract][Full Text] [Related]
108. Expression, localization and alternative splicing pattern of fibronectin messenger RNA in fibrotic human liver and hepatocellular carcinoma.
Matsui S; Takahashi T; Oyanagi Y; Takahashi S; Boku S; Takahashi K; Furukawa K; Arai F; Asakura H
J Hepatol; 1997 Nov; 27(5):843-53. PubMed ID: 9382972
[TBL] [Abstract][Full Text] [Related]
109. Soluble and insoluble fibronectin increases alveolar epithelial wound healing in vitro.
Garat C; Kheradmand F; Albertine KH; Folkesson HG; Matthay MA
Am J Physiol; 1996 Nov; 271(5 Pt 1):L844-53. PubMed ID: 8944729
[TBL] [Abstract][Full Text] [Related]
110. Differential expression of fibronectin splice variants, oncofetal glycosylated fibronectin and laminin isoforms in nodular palmar fibromatosis.
Kosmehl H; Berndt A; Katenkamp D; Mandel U; Bohle R; Gabler U; Celeda D
Pathol Res Pract; 1995 Nov; 191(11):1105-13. PubMed ID: 8822112
[TBL] [Abstract][Full Text] [Related]
111. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump.
Zaman GJ; Flens MJ; van Leusden MR; de Haas M; Mülder HS; Lankelma J; Pinedo HM; Scheper RJ; Baas F; Broxterman HJ
Proc Natl Acad Sci U S A; 1994 Sep; 91(19):8822-6. PubMed ID: 7916458
[TBL] [Abstract][Full Text] [Related]
112. P-glycoprotein (MDR 1 gene product) in cells of the immune system: its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection.
Gupta S; Gollapudi S
J Clin Immunol; 1993 Sep; 13(5):289-301. PubMed ID: 7902361
[TBL] [Abstract][Full Text] [Related]
113. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.
Alvarez M; Paull K; Monks A; Hose C; Lee JS; Weinstein J; Grever M; Bates S; Fojo T
J Clin Invest; 1995 May; 95(5):2205-14. PubMed ID: 7738186
[TBL] [Abstract][Full Text] [Related]
114. Molecular and biological interactions of fibronectin.
Ruoslahti E; Pierschbacher M; Engvall E; Oldberg A; Hayman EG
J Invest Dermatol; 1982 Jul; 79 Suppl 1():65s-68s. PubMed ID: 7045246
[TBL] [Abstract][Full Text] [Related]
115. The structure of fibronectin and its role in cellular adhesion.
Akiyama SK; Yamada KM; Hayashi M
J Supramol Struct Cell Biochem; 1981; 16(4):345-8. PubMed ID: 6273596
[TBL] [Abstract][Full Text] [Related]
116. Mucin Glycans: A Target for Cancer Therapy.
Sun L; Zhang Y; Li W; Zhang J; Zhang Y
Molecules; 2023 Oct; 28(20):. PubMed ID: 37894512
[TBL] [Abstract][Full Text] [Related]
117. Bittersweet Sugars: How Unusual Glycan Structures May Connect Epithelial-to-Mesenchymal Transition and Multidrug Resistance in Cancer.
Fonseca LMD; Diniz-Lima I; da Costa Santos MAR; Franklim TN; da Costa KM; Santos ACD; Morrot A; Decote-Ricardo D; Valente RDC; Freire-de-Lima CG; Dos Reis JS; Freire-de-Lima L
Medicines (Basel); 2023 Jun; 10(6):. PubMed ID: 37367731
[TBL] [Abstract][Full Text] [Related]
118. The Role of Integrins for Mediating Nanodrugs to Improve Performance in Tumor Diagnosis and Treatment.
Yu C; Jiang W; Li B; Hu Y; Liu D
Nanomaterials (Basel); 2023 May; 13(11):. PubMed ID: 37299624
[TBL] [Abstract][Full Text] [Related]
119. PDAC, the Influencer Cancer: Cross-Talk with Tumor Microenvironment and Connected Potential Therapy Strategies.
Mercanti L; Sindaco M; Mazzone M; Di Marcantonio MC; Piscione M; Muraro R; Mincione G
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296886
[TBL] [Abstract][Full Text] [Related]
120.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
